IL6 and COVID-19: The role of systemic inflammation in augmenting musculoskeletal pain, however, is also a likely contributing factor, particularly given the elevated levels of known nociceptive mediators, such as interleukin-6 (IL-6) in the sera of patients with COVID-19.